Therapeutic Targeting of DNA Replication Stress in Cancer

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)

(2023) Jingxue Yan et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer

(2022) Sushmita B. Gordhandas et al.   Scientific Reports

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs

(2022) Gérard Milano et al.   CANCER SCIENCE

Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy

(2022) Yoshihisa Matsumoto   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer

(2022) Mary Smithson et al.   NEOPLASIA

Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy

(2022) Sidney Veach Keisner   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

(2022) Kaidong Liu et al.   Molecular Oncology

Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins

(2021) Garri Manasaryan et al.   Cancers

Human RecQ Helicases in DNA Double-Strand Break Repair

(2021) Huiming Lu et al.   Frontiers in Cell and Developmental Biology

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy

(2021) Jolanta Kryczka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

WEE1 Inhibitor: Clinical Development

(2021) Anthony Kong et al.   Current Oncology Reports

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

(2021) Diana Zatreanu et al.   Nature Communications

DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer

(2021) Manni Wang et al.   Acta Pharmaceutica Sinica B

DNA-dependent protein kinase promotes DNA end processing by MRN and CtIP

(2020) Rajashree A. Deshpande et al.   Science Advances

Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma

(2020) Juliet E. Wolford et al.   GYNECOLOGIC ONCOLOGY

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

(2020) Frank T. Zenke et al.   MOLECULAR CANCER THERAPEUTICS

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA ‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

(2020) Mitchell S. Anscher et al.   ONCOLOGIST

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

(2019) Katrine Wallace et al.   PHARMACOECONOMICS

Templated Insertions: A Smoking Gun for Polymerase Theta-Mediated End Joining

(2019) Joost Schimmel et al.   TRENDS IN GENETICS

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells

(2019) Tatiana N. Moiseeva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PARP Inhibition in Cancer: An Update on Clinical Development

(2019) Esha Sachdev et al.   Targeted Oncology

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

(2019) Jacqueline H. L. Fok et al.   Nature Communications

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models

(2019) Hannah C. Wise et al.   Scientific Reports

Lesion Bypass and the Reactivation of Stalled Replication Forks

(2018) Kenneth J. Marians   Annual Review of Biochemistry

Topoisomerases as anticancer targets

(2018) Justine L. Delgado et al.   BIOCHEMICAL JOURNAL

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy

(2018) Gwynn Ison et al.   CLINICAL CANCER RESEARCH

The side effects of platinum-based chemotherapy drugs: a review for chemists

(2018) Rabbab Oun et al.   DALTON TRANSACTIONS

Assessment of DNA repair susceptibility genes identified by whole exome sequencing in head and neck cancer

(2018) Raima Das et al.   DNA REPAIR

Talazoparib: First Global Approval

(2018) Sheridan M. Hoy   DRUGS

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer

(2018) Ah-Rong Nam et al.   Cancer Research and Treatment

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response

(2017) Andrew N. Blackford et al.   MOLECULAR CELL

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Cell cycle-dependent phosphorylation regulates RECQL4 pathway choice and ubiquitination in DNA double-strand break repair

(2017) Huiming Lu et al.   Nature Communications

Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells

(2017) S Kumar et al.   Oncogenesis

Essential medicines for cancer: WHO recommendations and national priorities

(2016) Jane Robertson et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Validating the disruption of proliferating cell nuclear antigen interactions in the development of targeted cancer therapeutics

(2016) Shanna J. Smith et al.   CANCER BIOLOGY & THERAPY

The role of pharmacogenetics in capecitabine efficacy and toxicity

(2016) S.W. Lam et al.   CANCER TREATMENT REVIEWS

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

(2016) Timothy C. Johnstone et al.   CHEMICAL REVIEWS

Long-Term Renal Outcomes after Cisplatin Treatment

(2016) S. Latcha et al.   Clinical Journal of the American Society of Nephrology

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Essential Roles for Polymerase θ-Mediated End Joining in the Repair of Chromosome Breaks

(2016) David W. Wyatt et al.   MOLECULAR CELL

Targeting WEE1 Kinase in Cancer

(2016) Christopher J. Matheson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

RECQL4 Promotes DNA End Resection in Repair of DNA Double-Strand Breaks

(2016) Huiming Lu et al.   Cell Reports

A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy

(2016) Wenpeng Liu et al.   EBioMedicine

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links

(2015) Akshada Sawant et al.   DNA REPAIR

Mitoxantrone, More than Just Another Topoisomerase II Poison

(2015) Benny J. Evison et al.   MEDICINAL RESEARCH REVIEWS

Differential Phosphorylation of DNA-PKcs Regulates the Interplay between End-Processing and End-Ligation during Nonhomologous End-Joining

(2015) Wenxia Jiang et al.   MOLECULAR CELL

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

(2015) Raphael Ceccaldi et al.   NATURE

Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination

(2015) Pedro A. Mateos-Gomez et al.   NATURE

An Overview of the Molecular Mechanisms of Recombinational DNA Repair

(2015) Stephen C. Kowalczykowski   Cold Spring Harbor Perspectives in Biology

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells

(2015) Long Gu et al.   EBioMedicine

Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance

(2014) Robert G. Lingeman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

RECQ helicase RECQL4 participates in non-homologous end joining and interacts with the Ku complex

(2014) Raghavendra A. Shamanna et al.   CARCINOGENESIS

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Polymerase theta-mediated end joining of replication-associated DNA breaks in C. elegans

(2014) S. F. Roerink et al.   GENOME RESEARCH

A PCNA-Derived Cell Permeable Peptide Selectively Inhibits Neuroblastoma Cell Growth

(2014) Long Gu et al.   PLoS One

Association between RECQL5 genetic polymorphisms and susceptibility to breast cancer

(2014) Yu-Jun He et al.   TUMOR BIOLOGY

PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair

(2014) Y. Hu et al.   Cancer Discovery

Mechanism of Suppression of Chromosomal Instability by DNA Polymerase POLQ

(2014) Matthew J. Yousefzadeh et al.   PLoS Genetics

Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway

(2013) M. Aggarwal et al.   CANCER RESEARCH

DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology

(2013) Kahlin Cheung-Ong et al.   CHEMISTRY & BIOLOGY

The ATM protein kinase: regulating the cellular response to genotoxic stress and more

(2013) Yosef Shiloh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Structure of an ‘open’ clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport

(2013) Ivan Laponogov et al.   NUCLEIC ACIDS RESEARCH

Identification of Small Molecule Proliferating Cell Nuclear Antigen (PCNA) Inhibitor That Disrupts Interactions with PIP-box Proteins and Inhibits DNA Replication

(2012) Chandanamali Punchihewa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Topoisomerase as target for antibacterial and anticancer drug discovery

(2012) Muthu K. Kathiravan et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption

(2012) H. Beck et al.   MOLECULAR AND CELLULAR BIOLOGY

Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells

(2012) Juan J. García-Vallejo et al.   MOLECULAR IMMUNOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploiting bacterial DNA gyrase as a drug target: current state and perspectives

(2011) Frédéric Collin et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells

(2011) Zhiyong Mao et al.   CELL CYCLE

Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease

(2011) Raquel Domínguez-Kelly et al.   JOURNAL OF CELL BIOLOGY

Inhibition of Homologous Recombination by DNA-Dependent Protein Kinase Requires Kinase Activity, Is Titratable, and Is Modulated by Autophosphorylation

(2011) J. A. Neal et al.   MOLECULAR AND CELLULAR BIOLOGY

Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth

(2011) H. Zhao et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress

(2011) M. Aggarwal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation

(2010) Wojciech Strzalka et al.   ANNALS OF BOTANY

The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway

(2010) Michael R. Lieber   Annual Review of Biochemistry

The phosphoCTD-interacting domain of Topoisomerase I

(2010) Jianhong Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown

(2010) Geoff S. Higgins et al.   CANCER RESEARCH

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

DNA polymerase   up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability

(2010) F. Lemee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130

(2010) D. C. Hegan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry

(2010) Maxim Isabelle et al.   Proteome Science

Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma

(2009) W. Elliot Love et al.   ARCHIVES OF DERMATOLOGY

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

(2009) R. A. Daniel et al.   CLINICAL CANCER RESEARCH

Doxorubicin: The Good, the Bad and the Ugly Effect

(2009) Cristina Carvalho et al.   CURRENT MEDICINAL CHEMISTRY

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling

(2009) Ryan P. Topping et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Cyclophosphamide and cancer: golden anniversary

(2009) Ashkan Emadi et al.   Nature Reviews Clinical Oncology

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

(2009) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanism of Replication-Coupled DNA Interstrand Crosslink Repair

(2008) Markus Räschle et al.   CELL

DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

(2008) S. Ashwell et al.   CLINICAL CANCER RESEARCH

Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma

(2008) Stephanie L Wethington et al.   Expert Review of Anticancer Therapy

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Oncogene-Induced DNA Damage Model for Cancer Development

(2008) T. D. Halazonetis et al.   SCIENCE

Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair

(2008) Nicole Bennardo et al.   PLoS Genetics